甲状腺激素与非酒精性脂肪性肝病研究进展*

doi:10.3969/j.issn.1672-5069.2023.01.038

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)是肝硬化、肝癌和肝移植的重要原因。全球成年人患病率约为25％,且呈现上升趋势。大量的研究表明甲状腺激素(TH)在肝脏脂质代谢和胰岛素抵抗过程中起着重要的作用,甲状腺激素受体激动剂有望成为治疗NAFLD的新型药物。本文就甲状腺激素与NAFLD的研究进展进行了综述。

关键词: 非酒精性脂肪性肝病, 代谢相关脂肪性肝病, 甲状腺激素

Abstract: The nonalcoholic fatty liver disease (NAFLD) is considered to be the metabolic disorders in liver and is closely related to obesity, insulin resistance (IR), type 2 diabetes mellitus (T2DM) and hyperlipemia, etc. The prevalence of NAFLD among adults worldwide is about 25% and it is to believe increasing year by year. The NAFLD is an important causes of liver cirrhosis, liver cancer and liver transplantation. A large number of studies have shown that thyroid hormone (THs) plays an important role in hepatic lipid metabolism and IR, and the thyroid hormone receptor agonists are expected to become new medicines for the treatment of patients with NAFLD. In this review, we mainly discuss the progress of THs in patients with NAFLD.

Key words: Nonalcoholic fatty liver disease, Metabolic-associated fatty liver diseases, Thyroid hormone

陈怡, 朱友, 周希乔. 甲状腺激素与非酒精性脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2023, 26(1): 145-148.

Chen Yi,Zhu You,Zhou Xiqiao. Serum thyroid hormone levels in patients with nonalcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2023, 26(1): 145-148.

参考文献

[1] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018,67(1):328-357.
[2] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年版).实用肝脏病杂志,2018,21(2):177-186.
[3] Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond), 2018,18(3):245-250.
[4] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016,64(1):73-84.
[5] Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020,158(7): 1999-2014,e1.
[6] Kim D, Kim W, Joo SK, et al. Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis. Clin Gastroenterol Hepatol, 2018,16(1):123-131,e1.
[7] He W, An X, Li L, et al. Relationship between hypothyroidism and non-alcoholic fatty liver disease: A systematic review and Meta-analysis. Front Endocrinol (Lausanne), 2017,8:335.
[8] Pagadala MR, Zein CO, Dasarathy S, et al. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci, 2012,57(2):528-534.
[9] Eshraghian A, Hamidian Jahromi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World J Gastroenterol, 2014,20(25): 8102-8109.
[10] Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev, 2001,81(3):1097-1142.
[11] Fonseca TL, Fernandes GW, McAninch EA, et al. Perinatal deiodinase 2 expression in hepatocytes defines epigenetic susceptibility to liver steatosis and obesity. Proc Natl Acad Sci U S A, 2015,112(45):14018-14023.
[12] Fonseca TL, Fernandes GW, McAninch EA, et al. Perinatal deiodinase 2 expression in hepatocytes defines epigenetic susceptibility to liver steatosis and obesity. Proc Natl Acad Sci U S A, 2015,112(45):14018-14023.
[13] Gionfra F, De Vito P, Pallottini V, et al. The role of thyroid hormones in hepatocyte proliferation and liver cancer. Front Endocrinol (Lausanne), 2019,10:532.
[14] Sinha RA, Bruinstroop E, Singh BK, et al. Nonalcoholic fatty liver disease and hypercholesterolemia: Roles of thyroid hormones, metabolites, and agonists. Thyroid, 2019,29(9):1173-1191.
[15] Baumann CT, Maruvada P, Hager GL, et al. Nuclear cytoplasmic shuttling by thyroid hormone receptors. multiple protein interactions are required for nuclear retention. J Biol Chem,2001,276(14):11237-11245.
[16] Hönes GS, Rakov H, Logan J, et al. Noncanonical thyroid hormone signaling mediates cardiometabolic effects in vivo. Proc Natl Acad Sci U S A, 2017,114(52):E11323-E11332.
[17] Jornayvaz FR, Lee HY, Jurczak MJ, et al. Thyroid hormone receptor-α gene knockout mice are protected from diet-induced hepatic insulin resistance. Endocrinology, 2012,153(2):583-591.
[18] Araki O, Ying H, Zhu XG, et al. Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms. Mol Endocrinol, 2009, 23(3):308-315.
[19] Krause C, Grohs M, El Gammal AT, et al. Reduced expression of thyroid hormone receptor βin human nonalcoholic steatohepatitis. Endocr Connect, 2018, 7(12):1448-1456.
[20] Mashek DG. Hepatic fatty acid trafficking: multiple forks in the road. Adv Nutr, 2013,4(6):697-710.
[21] Feng X, Jiang Y, Meltzer P, et al.Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol, 2000, 14(7):947-955.
[22] Wang Y, Viscarra J, Kim SJ, et al. Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol, 2015,16(11):678-689.
[23] Grasselli E, Voci A, Demori I, et al. Triglyceride mobilization from lipid droplets sustains the anti-steatotic action of iodothyronines in cultured rat hepatocytes. Front Physiol, 2016,6:418.
[24] Simó R, Hernández C, Sáez-López C, et al. Thyroid hormone upregulates zinc-α2-glycoprotein production in the liver but not in adipose tissue. PLoS One, 2014,9(1):e85753.
[25] Sinha RA, You SH, Zhou J, et al. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J Clin Invest, 2012,122(7):2428-2438.
[26] Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol,2018,14(5):259-269.
[27] Ness GC, Pendleton LC, Li YC, et al. Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun,1990,172(3):1150-1156.
[28] Lopez D, Abisambra Socarrás JF, Bedi M, et al. Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochim Biophys Acta, 2007, 1771(9):1216-1225.
[29] Iannucci LF, Cioffi F, Senese R, et al. Metabolomic analysis shows differential hepatic effects of T2 and T3 in rats after short-term feeding with high fat diet.Sci Rep, 2017,7(1):2023.
[30] Chi HC, Tsai CY, Tsai MM, et al. Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases. J Biomed Sci, 2019,26(1):24.
[31] Bonde Y, Breuer O, Lütjohann D, et al. Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. J Lipid Res, 2014,55(11):2408-2415.
[32] Zhang X, Song Y, Feng M, et al. Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation via AMP-activated protein kinase in the liver. J Lipid Res, 2015,56(5):963-971.
[33] Song Y, Xu C, Shao S, et al. Thyroid-stimulating hormone regulates hepatic bile acid homeostasis via SREBP-2/HNF-4α/CYP7A1 axis. J Hepatol, 2015, 62(5): 1171-1179.

甲状腺激素与非酒精性脂肪性肝病研究进展^*

Serum thyroid hormone levels in patients with nonalcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄淡霞, 招志辉, 萧月兴, 何艳青. 小檗碱通过调节肠道菌群改善高脂饮食诱导的非酒精性脂肪性肝病大鼠肝组织炎症实验研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 23-26.
[2]	陈凤莲, 朱青蓝, 朱伶俐, 陈国飞. 非酒精性脂肪性肝病患者外周血恒定自然杀伤T细胞和CD4⁺/CD8⁺T细胞活化差异研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 31-34.
[3]	徐伟强, 刘淑萍, 李潇萌. 体检人群非酒精性脂肪性肝病检出率及其危险因素分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 35-38.
[4]	李向阳, 丁光伟, 靳铭. 恩替卡韦治疗慢性乙型肝炎合并NAFLD患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 776-779.
[5]	孙峥, 王笑烨, 袁景, 梁丽. 达格列净联合利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 796-799.
[6]	蔡勇, 李璟, 欧琴. 2型糖尿病合并非酒精性脂肪性肝病患者血清网膜素、视黄醇结合蛋白4和Ⅰ型原胶原氨基端前肽水平及意义分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 800-803.
[7]	孙凌, 杭玮, 邓国忠. 二甲双胍联合吡格列酮治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 804-807.
[8]	王晓华, 曾雅琳, 郭萃蓉. 非酒精性脂肪性肝病进展性肝纤维化患者空腹血糖受损和胰岛素抵抗调查^*[J]. 实用肝脏病杂志, 2022, 25(6): 812-815.
[9]	樊叶, 张喜梅, 张岩. 非酒精性脂肪性肝病患者血清胱抑素C、脂蛋白α和nesfatin-1水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(6): 816-819.
[10]	曾婷, 雷向阳, 白晓苏. 氧化苦参碱对非酒精性脂肪性肝病大鼠肝脏保护作用研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 624-627.
[11]	刘彦彤, 姚杨, 卢博. 荷叶调脂疏肝汤对非酒精性脂肪性肝病患者脂代谢的影响研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 657-660.
[12]	奚佳颖, 汤佳美, 刘玲玉, 王韦. 超声三维斑点追踪技术评价非酒精性脂肪性肝病合并2型糖尿病患者左心功能研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 661-664.
[13]	潘飞, 寿涓, 张冬青. 不同他汀类药物治疗非酒精性脂肪性肝病合并高脂血症患者效果分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 665-668.
[14]	王慧, 汤展, 常文娟, 芦超. 非肥胖型与肥胖型非酒精性脂肪性肝病患者代谢特征和肝脂肪变程度比较^*[J]. 实用肝脏病杂志, 2022, 25(5): 669-672.
[15]	陈梦绮, 范建高. 美国非酒精性脂肪性肝病诊断与治疗临床实践指南简介^*[J]. 实用肝脏病杂志, 2022, 25(5): 0-S16.